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Parkinson's disease (PD) is a chronic neurodegenerative disease, and there is no cure 
for it at present. Recent research has indicated a link between type 2 diabetes mellitus 
(T2DM) and PD, which suggested that a treatment to improve insulin resistance for 
T2DM may be useful for PD patients. Glucose-dependent insulinotropic polypeptide 
(GIP) belongs to the incretin hormone family, which can promote insulin release and 
improve insulin resistance. Several GIP analogues have been developed as potential 
treatments for T2DM. In the present study, a novel long- lasting GIP analogue, 
D-Ala2-GIP-glu-PAL, has been tested in an acute PD mouse model induced by four 
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intraperitoneal injections. 
D-Ala2-GIP-glu-PAL treatment (25nmol/kg ip.) for 7 days after MPTP treatment 
improved the locomotor and exploratory activity of mice, and improved bradykinesia 
and movement balance of mice. D-Ala2-GIP-glu-PAL treatment also restored tyrosine 
hydroxylase (TH) positive dopaminergic neuron numbers in the substantia nigra and TH 
levels in the striatum. D-Ala2-GIP-glu-PAL also reduced the chronic inflammation 
response as seen in astrocyte and microglia activation in the substantia nigra pars 
compacta (SNpc). D-Ala2-GIP-glu-PAL reversed the reduction of synapse numbers 
(synaptophysin levels), decreased the ratio of growth factor and apoptosis signaling 
molecules Bax/Bcl-2, and improved the decrease of p-CREBS133 growth factor signaling 
in the substantia nigra. Therefore, D-Ala2-GIP-glu-PAL promotes cell survival of 
dopaminergic neuron in the SNpc by activating the cAMP/PKA/CREB growth factor 
second messenger pathway that also inhibits apoptosis. The present results 
demonstrate that D-Ala2-GIP-glu-PAL shows promise as a novel treatment of PD. 
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Parkinson's disease (PD) is the second most common chronic neurodegenerative 
disease afflicting about 1% of people over 65 years old and 4-5% of people over 85 
years. The pathology of PD is characterized by a progressive loss of dopaminergic 
neurons in the substantia nigra pars compacta (SNpc) and the degeneration of 
projecting nerve fibers to the striatum, which leads to tremors, muscular rigidity, 
bradykinesia, and postural and gait abnormalities (Kowal et al., 2013). Current 
treatment strategies for PD have mostly targeted the dopamine system. Levodopa is 
the most effective drug used in the treatment of PD. However, the long-term use of 
levodopa produces complications such as highly disabling fluctuations of motor activity 
and dyskinesias (Sharma et al., 2015). Other treatment options include dopamine 
agonists, anticholingergics, amantadine, monoamine oxidase (MAO) inhibitors, and 
deep brain stimulation (Giugni and Okun, 2014). However, neuroprotective treatments 
that delay or cure PD remain an unrealised goal.  
Recently, studies have shown a link between diabetes and PD. Both diabetes and PD 
are age-related chronic diseases and some pathogenic processes may underlie both 
conditions (Chen et al., 2008; Henchcliffe and Beal, 2008; Pradhan, 2007). Insulin 
de-sensitisation may be one mechanism that underlies both conditions. Clinical data 
evaluation showed that an 8–30 percentage of PD patients were diabetic, a significantly 
higher percentage compared to age matched controls (Cereda et al., 2011; Hu et al., 
2007; Miyake et al., 2010; Schernhammer et al., 2011). PD and diabetes also share 
several genetic susceptibilities, such as single nucleotide polymorphisms in the growth 
factor signaling kinase gene Akt, which increase an individual’s risk for developing PD 
and diabetes (Jain et al., 2012; Xiromerisiou et al., 2008). Common pathways that link 
PD, diabetes, and inflammation have been identified by genome-wide transcriptome 
profiling (Moran and Graeber, 2008). In preclinical studies, systemic administration of 
drugs for T2DM, such as insulin (Holscher, 2014b), rosiglitazone (Schintu et al., 2009), 
and metformin (Patil et al., 2014), significantly attenuate neuropathology, including the 
loss of SNpc neurons and the striatal dopaminergic fibers, microglial activation, or the 
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expression of pro-inflammatory cytokines. Also, a drug that is on the market to treat 
type 2 diabetes, Exenatide (exendin-4), showed a therapeutic effect in preclinical tests 
(Harkavyi et al., 2008; Kim et al., 2009; Li et al., 2009) and in a pilot clinical trial in PD 
patients (Aviles-Olmos et al., 2013a; Aviles-Olmos et al., 2014). In light of these recent 
findings, a hypothesis has emerged that suggests that mitochondrial dysfunction, 
endoplasmic reticulum stress, inflammation, and alterations in metabolism may lead to 
insulin resistance and, ultimately, to diabetes and/or neurodegeneration (Lima et al., 
2014; Santiago and Potashkin, 2013). Hence, the treatment to improve insulin 
resistance for T2DM may be useful for PD patients (Aviles-Olmos et al., 2013b; Holscher, 
2014b). 
Glucose-dependent insulinotropic polypeptide (GIP), also named gastric inhibitory 
polypeptide, is an endogenous 42 amino acid peptide hormone (Baggio and Drucker, 
2007). GIP belongs to the incretin family, which can promote insulin release and lower 
blood glucose, and has growth factor like properties (Holscher, 2014a). As GIP is quickly 
degraded by the enzyme dipeptidyl peptidase IV (DPP-IV) in the blood stream (Kieffer 
et al., 1995), several enzyme-resistant GIP analogues have been developed, such as 
D-Ala2GIP and D-Ala2-GIP-GLU-PAL, as potential treatments for type 2 diabetes (Irwin 
et al., 2006a).  
In the central nervous system, GIP is expressed in neurons and acts as a 
neurotransmitter, and GIP receptors are also found in multiple brain regions, including 
the olfactory bulb, hippocampus, cerebellum, cerebral cortex, substantia nigra, 
thalamus, and brainstem (Nyberg et al., 2005; Nyberg et al., 2007). Activation of the 
GIPR leads to proliferation of neuronal progenitor cells and therefore may contribute to 
neurogenesis (Holscher, 2014b). GIP not only has growth-factor like properties in the 
brain, but also modulates synaptic activity. GIP prevented the detrimental effects of 
beta-amyloid on synaptic plasticity (LTP) in the hippocampus (Gault and Holscher, 2008) 
and on spatial learning and memory (Figueiredo et al., 2010). Furthermore, GIP has 
been shown to promote axonal regeneration after sciatic nerve injury (Buhren et al., 
2009). In our previous study, chronic injection of D-Ala2GIP enhanced memory 
formation, synaptic neurotransmission (LTP) in the hippocampus, and progenitor cell 
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proliferation in the dentate gyrus of wild type mice and mice on a high-fat diet (Faivre 
et al., 2012; Porter et al., 2011). Moreover, D-Ala2GIP can improve cognitive function 
and prevent deficits of learning and memory in APP/PS1 transgenic mice, and reduces 
the beta amyloid plaque load and neuroinflammation in the brain. Synaptic plasticity 
and synapse numbers were also normalised by the drug (Duffy and Holscher, 2013; 
Faivre and Holscher, 2013a, b).  
Although GIP analogues showed a potential therapeutic effect for AD in animal 
experiments, the protective effects in PD have not been investigated. In the present 
study, a new long lasting GIP analogue, D-Ala2-GIP-GLU-PAL, was tested in an acute PD 
mouse model induced by 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).  
 
2. Materials and methods 
 
2.1 Chemicals and peptides 
Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) were purchased from 
Sigma-Aldrich (St Louis, MO, USA). Other chemicals used were of the highest quality 
commercially available. D-Ala2-GIP-GLU-PAL was purchased from GL Biochem Ltd 
(Shanghai). The purity of the peptide was analysed by reversed-phase high performance 
liquid chromatography (HPLC) and characterised using matrix-assisted laser 






(PAL = C16 fatty acid) 
 
2.2 Animals and drug treatments 
Male C57BL/6 mice (20–25 g) were purchased from the Academy of Military Medical 
Sciences (AMMS, China). The animals were maintained on 12-h light/dark cycle at 
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24 ℃ ± 1℃ and 55 ± 5% humidity with food and water ad libitum, and were 
acclimatized for at least 1 week prior to the MPTP procedure. All experimental 
procedures involving animals in the present study were approved by the Institutional 
Animal Care Committee of Shanxi Medical University and conform to the guidelines of 
National Institute of Health (NIH) guideline (NIH publication NO. 85-23. Revised 1985). 
Mice were divided into four different groups (n=8 per group) consisting of (i) a control 
group treated with saline alone; (ii) a group treated with D-Ala2-GIP-GLU-PAL; (iii) a 
group treated with MPTP alone; and (iv) a group treated with D-Ala2GIP-GIP-Glu-PAL in 
combination with MPTP. Mice received four intraperitoneal injections of MPTP (20 
mg/kg body weight; Sigma-Aldrich) or saline (0.9%) control at 2-h intervals. 
D-Ala2-GIP-GLU-PAL was dissolved in saline and drug (25nmol/kg body weight) ip. 
injection continued for 7 days after MPTP injection. Control mice received equal 
volumes of the vehicle solution. At the end of drug treatments, measurements of 
behavioral changes, neuronal damage, inflammatory markers, and biomarkers were 
made.  
 
2.3 Behavioral assessment 
2.3.1 Open-field test 
To assess locomotor and exploratory activity of PD mice, the open-field test was 
conducted on the 6th day after MPTP treatment as previously described (Rial et al., 
2014). The open-field apparatus consisted of a square arena (50 cm*50 *cm *40 cm) 
with a floor divided into 25 equal-sized squares with grids. Each rat was placed in the 
center of the apparatus and was observed. After acclimatizing 10 min, the number of 
crossing line and rearings made by the animal was recorded within 5 min. The 
apparatus was then cleaned with 70% alcohol and dried between trials. The 
experiment was repeated 2 times for each animal, and the average of 2 trials was 
calculated for statistical analyses. 
 
2.3.2 Pole test 
To determine the degree of bradykinesia and ability to movement balance of PD mice, 
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the pole test was conducted on the 5th day after MPTP treatment as previously 
described (Park et al., 2013). In brief, animals were placed facing upward near the top 
of a wooden pole with a rough surface (10 mm in diameter and 55 cm in height). The 
time taken until they turned completely downward (defined as turn time, T-turn) and 
the time taken to arrive at the floor (locomotor activity time, T-LA) were recorded. If 
the mouse did not descend in 30s, it was guided, and T-turn was recorded as 30s. The 
mice were pre-trained before MPTP injections. Every mouse was tested for 3 times and 
the average of the three trials was calculated for statistical analyses.   
 
2.4 Sample preparation 
All animals were sacrificed on the 7th day after MPTP injection. After anesthetization 
with ethyl carbamate, whole brains of 4 mice per group were removed immediately 
and substantia nigra was dissected out and stored at −80 °C for immunoblot analysis. 
And another 4 mice per group were transcardial perfused with ice-cold PBS and 4% 
paraformaldehyde/PBS (pH7.4), and brains were removed and postﬁxed for 24 h in the 
same ﬁxative, and the brains were embedded in paraffin.  
 
2.5 Immunohistochemistry   
Brain tissue samples were embedded in paraffin, and sections were cut at 4 μm with a 
microtome. The sections encompassing the SNpc and the striatum were placed on 
coated slides. Paraffin was removed from the tissue sections with xylene, and the 
sections were rehydrated in graded ethanol solutions. Endogenous peroxidase activity 
was blocked with 3% H2O2 for 5 min. Antigen retrieval was performed by heating in 10 
mmol/L citrate buffer (pH 6.0) for 10 min. After blocked with 5% BSA, sections were 
incubated with the primary antibody for TH (rabbit anti-TH; 1:500; Abcam, Cambridge, 
UK), GFAP (rabbit anti-GFAP; 1:100; Boster Biotechnology Co., Ltd. Wuhan, China) and 
IBA1 (goat anti-IBA1; 1:500; Abcam, Cambridge, UK) at 37℃ for 1h. They were rinsed 
in PBS and incubated with biotinylated goat anti-rabbit IgG or biotinylated rabbit 
anti-goat IgG at 37℃ for 0.5h and incubated with followed by the avidin-biotin 
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peroxidase complex reagent (Boster Biotechnology Co., Ltd. Wuhan, China) at 37℃ for 
0.5h. Samples were colored in 3,3-diaminobenzidine (DAB) solution in the presence of 
H2O2 (Zhongshan Golden Bridge Biotechnology Co., Ltd. Beijing, China). To verify the 
immune specificity, control sections were processed with the same protocol, except 
that omitting the primary antibody. All stained sections were viewed and 
photographed under a Zeiss light microscope, and images were captured by digital 
camera (Motic BA210). 
Quantitative analysis of DA neurons in SNpc was carried out by serial section analysis of 
the total number of TH positive (TH+) neurons throughout the rostro-caudal axis. Only 
the region corresponding to the SNpc was carefully delineated, according to the mouse 
brain atlas of Paxinos (Paxinos et al., 1999). Optical density of dopaminergic neuron 
termini in the striatum were determined from scanned TH+ sections by digital 
densitometry using Image-pro plus6.0 software. The areas of GFAP or IBA1 positive 
cells were determined using Image-pro plus6.0 software. 
 
2.6 Western blot   
Western blot assay was performed using standard protocols. Midbrain tissues 
containing substantia nigra were homogenized on ice in RIPA lysis buffer (Beyotime 
Institute of Biotechnology, Shanghai, China) containing phenyl-methylsulfonyl fluoride 
(PMSF). After 30 min, tissue lysates were obtained by centrifugation at 12000 rpm for 5 
min at 4°C. The protein concentration of the samples then was quantified by BCA 
protein assay (Beyotime Institute of Biotechnology, Shanghai, China), using bovine 
serum albumin as standard. After tissue lysate was mixed in loading buffer and boiled 
for 5 min, equivalent amounts of protein were separated on 12% or 10% 
SDS-polyacrylamide gel and transferred to polyvinylidene difluoride (PVDF) membranes. 
The membranes were blocked with 5%BSA in Tris-buffered saline (Boster Biotechnology 
Co., Ltd. Wuhan, China) and incubated overnight at 4°C with rabbit anti-mouse 
synaptophysin (SYN)(1:5000; Abcam, Cambridge, UK), rabbit anti-mouse Bcl-2 (1:400; 
Boster Biotechnology Co., Ltd. Wuhan, China), rabbit anti-mouse Bax (1:400; Boster 
Biotechnology Co., Ltd. Wuhan, China), rabbit anti-mouse p-CREBS133 (1:500; Abcam, 
Neuroprotective effects of D-Ala2-GIP-GLU-PAL 
 9 
Cambridge, UK) and rabbit anti-mouse CREB (1:500; Abcam, Cambridge, UK), followed 
by incubation for 2h at room temperature with the HRP-labeled goat anti-rabbit 
immunoglobulin (1:1000; Abcam, Cambridge, UK). The bound antibodies were then 
visulalized by ECL-enhanced chemilluminescence (Beyotime Institute of Biotechnology, 
Shanghai, China) according to the manufacturer’s instructions. In some cases, the blots 
were stripped and reprobed with an rabbit anti-mouseβ-actin (1:1000; Abcam, 
Cambridge, UK) to ensure equal sample loading. Western blot images were captured 
with a chemiluminescent imaging system (Sagecreation, Beijing, China). All bands were 
quantified using the image system of Quantity one 4.31(Bio-Rad, Hercules, CA, USA). 
 
2.7 Statistical analysis  
 
All data were expressed as means ± S.E.M. All analysis was conducted using GraphPad 
Prism (Graph-Pad software Inc., San Diego, CA, USA). Statistical signiﬁcance was 
performed by one-way ANOVA for multiple comparisons followed by Bonferroni’s 





3.1 D-Ala2-GIP-GLU-PAL normalised the MPTP-induced impairments in locomotor and 
exploratory activity of mice 
 
A one-way ANOVA found an overall difference between groups (P<001). The results 
showed that the number of crossings in MPTP group mice exhibited a significant 
reduction versus the control group mice (P<0.01 in the Bonferroni’s post hoc test). 
However, D-Ala2-GIP-GLU-PAL treatment reversed these effects on crossing (P<0.01). 
MPTP procedure also decreased the number of rearing (P<0.01), and 
D-Ala2-GIP-GLU-PAL could improve the rearing number (P<0.05). Each group was n=8, 
see fig. 1A.  
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3.2 D-Ala2-GIP-GLU-PAL improved the bradykinesia and movement imbalance of mice 
induced by MPTP  
A one-way ANOVA found an overall difference between groups (P<001). MPTP injection 
induced the bradykinesia of mice, with more time to turn at the top (T-turn) (P<0.001) 
compared with the control. And MPTP injection also induced movement imbalance of 
mice, with more time to climb down (T-LA) (P<0.001) compared with the control. 
However, treatment with D-Ala2-GIP-GLU-PAL significantly reversed these effects 
induced by MPTP (P<0.01). N=8 per group, see fig. 1B. 
 
3.3 D-Ala2-GIP-GLU-PAL protected dopaminergic neuronal damage induced by MPTP 
A one-way ANOVA found an overall difference between groups (P<001). On the 7th day 
after MPTP injection, the number of TH-positive cells in the SNpc was decreased to 
27.00% (P<0.001), and the average optical density of TH staining in the striatum was 
decreased to 56.86% (P<0.001). There is no difference between control group and 
D-Ala2-GIP-GLU-PAL group. However, D-Ala2-GIP-GLU-PAL treatment restored numbers 
of dopaminergic neurons to 59.4% in SNpc (P<0.05) and the overall levels of TH to 
83.64% in the striatum (P<0.01) in MPTP-treated mice. See fig. 2. 
 
3.4 D-Ala2-GIP-GLU-PAL reduced the chronic inflammation and astrocyte and 
microglia activation in the substantia nigra induced by MPTP 
A one-way ANOVA found an overall difference between groups (P<001). Anti-GFAP was 
used as an indicator of activated astrocytes. GFAP-positive astrocytes covered an 
average of 2.38% of each section in the SNpc of control mice, and covered an average 
of 2.81% in alone D-Ala2-GIP-GLU-PAL injection group. There was no difference 
between control and alone D-Ala2-GIP-GLU-PAL injection group. GFAP levels increased 
to 13.10% after MPTP treatment, which was significantly higher than in control mice 
(P< 0.001). While D-Ala2-GIP-GLU-PAL treatment made the areas of GFAP-positive 
astrocytes decrease to 4.74%, which was significantly less than MPTP group (P<0.001). 
See fig. 3A. 
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Anti-IBA1 was used as a biomarker for microglia activation. IBA1-positive microglia 
covered an average of 0.57% of each section in the SNpc of control mice, and covered 
an average of 0.63% in alone D-Ala2-GIP-GLU-PAL injection group. There was no 
difference between control and alone D-Ala2-GIP-GLU-PAL injection group. This was 
rise to 4.85% by MPTP procedure, which was significantly higher than control mice (P< 
0.001). While D-Ala2-GIP-GLU-PAL treatment made the areas of IBA1-positive microglia 
decrease to 1.83%, which was significantly less than MPTP group (P<0.001). N=4 per 
group, see fig. 3B. 
 
3.5 D-Ala2-GIP-GLU-PAL reversed the reduction of synaptophysin levels in the 
substantia nigra of mice induced by MPTP 
A one-way ANOVA found an overall difference between groups (P<001). The marker for 
synapse numbers, synaptophysin (SYN), was much reduced in mice treated with MPTP 
(P<0.001) compared to control. D-Ala2-GIP-GLU-PAL treatment partially reversed the 
reduction (P<0.01) compared to the MPTP group. N=4 per group, see fig. 4. 
 
3.6 D-Ala2-GIP-GLU-PAL reversed the increase of Bax/Bcl-2 levels in the substantia 
nigra of mice induced by MPTP. 
A one-way ANOVA found an overall difference between groups (P<001). The overall 
levels of the anti-apoptotic signaling molecule Bcl-2 in SNpc was reduced by MPTP 
treatment, levels of the pro-apoptotic signaling molecule Bax in SNpc was increase by 
MPTP treatment, and ratio of Bax/Bcl-2 was increased (P<0.01), compared with control 
group. While D-Ala2-GIP-GLU-PAL partly decreased the ratio of Bax/Bcl-2 by enhancing 
Bcl-2 levels (P<0.01). N=4 per group, see fig. 5. 
 
3.7 D-Ala2-GIP-GLU-PAL moderate reversed the decrease of p-CREBS133 in the 
substantia nigra of mice induced by MPTP. 
The levels of total CREB did not change in any of the groups. The level of p-CREBS133 in 
alone D-Ala2-GIP-GLU-PAL group was slight higher than control group, but there was no 
significance (P>0.05). There was a significant decrease in levels of p-CREBS133 in 
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MPTP-treated group (P<0.001), compared with control group. However, 
D-Ala2-GIP-GLU-PAL treatment moderate reversed the decrease (P<0.05). N=4 per 






In our study we show for the first time that GIP receptor activation has neuroprotective 
effects in an animal model of PD. We have previously shown that a protease resistant 
GIP analogue has protective effects in a mouse model of Alzheimer’s disease (Duffy and 
Holscher, 2013; Faivre and Holscher, 2013a, b), but no data has been published 
previously that demonstrates that GIP analogues may also have protective effects in PD. 
In the present study, the optimal dose of D-Ala2-GIP-GLU-PAL (25nmol/kg body weight) 
for the evaluation of the neuroprotective effects in the PD mouse model was selected 
based on the previous findings (Faivre et al., 2012; Irwin et al., 2006b; Martin et al., 
2013; Tatarkiewicz et al., 2014). We chose the MPTP mouse of PD model for testing this 
novel GIP analogue. MPTP is a commonly used chemical to induce a Parkinson-like 
state in rodents (Kopin and Markey, 1988; Nakamura and Vincent, 1986). It was 
discovered when a contaminated batch of heroin was sold in New York and the users 
developed PD like symptoms (Langston et al., 1999; Morin et al., 2014). MPTP is 
lipophilic and can cross the blood–brain barrier. There, MPTP is metabolised into the 
toxic cation 1-methyl-4-phenylpyridinium (MPP+) by the monoamine oxidase B (Glover 
et al., 1986). MPP+ kills primarily dopamine-producing neurons in the substantia nigra, 
pars compacta (Gerlach et al., 1991; Nakamura and Vincent, 1986). MPP+ interferes 
with complex 1 of the mitochondrial electron transport chain, which leads to the 
production of free radicals and eventually to neuronal death in the SN (Kinemuchi et al., 
1987; Smith and Bennett, 1997). As animals do not naturally develop PD, the MPTP 
lesion model is one of several models that are in use to investigate the underlying 
mechanisms of PD and also to test new drug candidates for their neuroprotective 
properties (Morin et al., 2014).   
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Locomotor dysfunction including tremors, rigidity and bradykinesia are the classic 
clinical symptoms of PD. In the present study, open field test analysis suggests that 
D-Ala2-GIP-GLU-PAL improved the locomotor and exploratory activity of mice induced 
by MPTP, and the improved bradykinesia, movement coordination and balance of mice 
also were shown in the pole test. The impairment in locomotor performance was 
consistent with the reduced levels of TH proein levels. On the 7th day after acute MPTP 
injection, the number of TH-positive cell bodies in the SNpc was decreased to 27.00%, 
and the level of TH in the striatum was decreased to 56.86%. However, 
D-Ala2-GIP-GLU-PAL treatment restored numbers of TH positive neurons to 59.4% in 
SNpc and the nerve fibers to 83.64% in the striatum. As TH is a key enzyme in the 
dopamine synthesis, the changes in TH levels indicate a reduction in the synthesis of 
dopamine in SNpc neurons. Furthermore, as shown in the results of synapse numbers 
biomarker synaptophysin, the synapse numbers are reduced by the MPTP treatment, 
and D-Ala2-GIP-GLU-PAL was able to partially prevent or reverse this effect. Similar 
protection of synapse numbers and of synaptic plasticity by GIP analogues was 
observed in a mouse model of AD (Faivre and Holscher, 2013a, b; Gault and Holscher, 
2008). The results demonstrate protective effects of D-Ala2-GIP-glu-PAL on synapses 
and synaptic function in the MPTP treated mice.  
A key element of disease progression in PD is the development of a chronic 
inflammation response in the brain. The reduction of inflammation in the brain was 
shown by the reduced levels of GFAP levels in astrocytes and IBA1 in microglia after 
D-Ala2-GIP-glu-PAL treatment. High concentrations of pro-inflammatory cytokines such 
as interleukin (IL)-1b, IL-6, and tumor necrosis factor (TNF)-α have been found in the 
brain, cerebral spinal fluid, and blood of PD patients (Chen et al., 2008). Chronic 
inflammation is thought to play a central role in PD pathogenesis because the release 
of cytokines promotes disease progression (Ferrari and Tarelli, 2011). Initially, an acute 
inflammatory response may be beneficial to clear out necrotic cells. Once the chronic 
inflammation is established, however, the inflammation response becomes neurotoxic 
due to the production of free radicals and pro-inflammatory cytokines. Abnormal 
production of pro-inflammatory cytokines by activated microglia and astrocyte can lead 
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to synapse dysfunction and ultimately synapse loss (Tansey and Goldberg, 2010). We 
previously reported that another GIP analogue, D-Ala2-GIP, also decreased 
neuroinflammation in the cortex of APP/PS1 mice (Duffy and Holscher, 2013). The 
reduction of the inflammation response is most likely one of the mechanisms by which 
GIP analogues exert their neuroprotective effects.  
Apoptosis also plays a role in neurodegenerative disorders such as PD. GIP acts as an 
endogenous neurotrophic factor and supports neuronal survival (Holscher, 2014a; 
Maino et al., 2014; Paratore et al., 2011); and in cultured cerebellar granule neurons, 
GIP reduced the extent of apoptotic death (Paratore et al., 2011). As neurons in the SN 
are not replaced, the inhibition of apoptotic signaling will be of benefit (Schulz, 2006). 
MPTP has been shown to induce apoptosis by inhibiting the mitochondrial 
multi-subunit enzyme complex I (Bove and Perier, 2012). We analysed the protein 
levels of the anti-apoptotic signaling molecule Bcl-2 (Maino et al., 2014) and the 
pro-apoptotic signaling molecule Bax (Kim et al., 2005) in the SNpc in this study. MPTP 
treatment led to a decline of Bcl-2 levels and an increase of Bax in the SNpc, and 
D-Ala2-GIP-glu-PAL partly reversed this process by promoting Bcl-2 expression. Previous 
studies have shown that GIP enhances cell survival and increases Bcl-2 levels in 
cultured neurons (Maino et al., 2014) and in islet beta cells (Kim et al., 2005; Lupi et al., 
2010). Other studies showed that GIP promotes the survival of cells by increasing Bcl-2 
promoter activity and upregulating the synthesis of Bcl-2 in vivo or in vitro (Kim et al., 
2008). Microarray analysis of GIP treated cells also showed down-regulation of Caspase 
8 associated protein 2, a multifunctional protein of the cysteine proteases family which 
plays a key role in apoptosis. Additionally, GIP treatment up-regulated the expression of 
cytoglobin, a protein involved in the antioxidant defense system and regulation of 
apoptosis (Maino et al., 2014). Therefore, D-Ala2-GIP-glu-PAL may promote cell survival 
of dopaminergic neurons in the SNpc by blocking apoptosis induced by MPTP.  
  GIP receptors activate an adenylyl- cyclase and enhance intracellular cAMP levels, 
which in turn activates Protein Kinase A (PKA), which phosphorylates the 
cAMP-response element binding protein (CREB) at Serine 133 and the 
cAMP-responsive CREB coactivator 2 (TORC2) through a pathway involving 
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phosphatidylinositol 3-kinase (PI3-K), PKB, and AMP-activated protein kinase (AMPK) 
(Holscher, 2014b; Kim et al., 2010). The cAMP/PKA/CREB cell signaling cascade is a 
classic growth-factor cell signaling cascade (Hussain et al., 2006; Li et al., 2010), and 
plays a regulatory role in the nervous system and promotes neuronal survival, 
precursor cell proliferation and synaptic activity (Holscher, 2014b; Sharma et al., 2013). 
An impairment in the CREB-induced transcription cascade correlates with neuronal loss 
and the resulting motor disorders in PD (Kano et al., 1995). GIP stimulates expression of 
the anti-apoptotic Bcl-2 gene in pancreatic beta cells through a pathway involving 
AMP-activated protein kinase (AMPK), TORC2, and CREB (Holscher, 2014a; Kim et al., 
2008). We therefore analysed the levels of CREB phosphorylation at serine 133 in the 
SNpc. There was a significant decrease in levels of p-CREBS133 in the MPTP-treated 
group. The result was consistent with previous studies (Sa et al., 2015). However, 
D-Ala2-GIP-glu-PAL treatment partially reversed the decrease of p-CREBS133 levels. 
These findings demonstrate that D-Ala2-GIP-GLU-PAL can facilitate CREB activation, and 
ultimately promote cell survival of dopaminergic neuron in SNpc. Further research is 
required to elucidate the cellular signaling pathways that are involved in 
neurodegeneration in PD and in neuroprotection by GIP analogues. 
The MPTP mouse model is considered an animal model of PD, but it has its limitations 
and does not recapitulate all pathological processes found in PD. The results presented 
here show that GIP analogues hold promise as a potential treatment for PD. Further 
tests will be conducted in other animal models of PD using different chemicals to 
induce PD- like symptoms such as 6-OHDA or LPS injection into the brain, and 
transgenic mouse models that express human mutated genes that are known to induce 
PD. 
 
In conclusion, the results from the in vivo PD mouse models demonstrate the 
neuroprotective effects of D-Ala2-GIP-glu-PAL and provide insight into its mechanism of 
action. Our findings demonstrate that treatment with D-Ala2-GIP-glu-PAL significantly 
inhibits MPTP-induced Parkinsonism-like symptoms in mice. D-Ala2-GIP-glu-PAL also 
reduces MPTP-induced damage in the dopaminergic neurons in this mouse model. 
Neuroprotective effects of D-Ala2-GIP-GLU-PAL 
 16 
Moreover, the neuroprotective activity of D-Ala2-GIP-glu-PAL may result from 
increasing CREB-mediated Bcl-2 expression to prevent apoptosis and from the 
reduction of chronic neuroinflammation. Long-acting GIP analogues hold promise as 
novel treatments that not only improve the symptoms but prevent the 
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Fig. 1A: D-Ala2-GIP-GLU-PAL protects from the MPTP-induced impairment in motor 
activity and exploration of mice. A difference was found between the control group and 
MPTP group. Furthermore, a difference was found between MPTP + 
D-Ala2-GIP-GLU-PAL and MPTP group.  
Fig. 1B: D-Ala2-GIP-GLU-PAL improved the bradykinesia and unbalance of mice induced 
by MPTP. The values represent the means ± S.E.M.; ***P<0.001 compared with the 
control group. #P<0.05, ## P<0.01, and ###P<0.001 compared with the MPTP group. n=8 
per group.  
 
Fig. 2 top: D-Ala2-GIP-GLU-PAL restored tyrosine hydroxylase (TH) positive 
dopaminergic neuron numbers in the substantia nigra. (A – D) – TH positive neuron 
numbers were reduced following treatment with MPTP, and increased by 
D-Ala2-GIP-GLU-PAL. A: Saline; B: D-Ala2-GIP-GLU-PAL; C: MPTP; D: MPTP + 
D-Ala2-GIP-GLU-PAL. Scale bar in image C: 200μm. Graph: D-Ala2-GIP-GLU-PAL 
treatment restored numbers of dopaminergic neurons in MPTP-treated mice.  
Fig. 2 bottom: D-Ala2-GIP-GLU-PAL restored tyrosine hydroxylase (TH) expression in the 
striatum. (A – D) – TH positive nerve fibers were reduced following treatment with 
MPTP, and increased by D-Ala2-GIP-GLU-PAL. A: Saline; B: D-Ala2-GIP-GLU-PAL; C: MPTP; 
D: MPTP + D-Ala2-GIP-GLU-PAL. Scale bar in image C: 500μm. Graph: 
D-Ala2-GIP-GLU-PAL treatment restored levels of TH staining in MPTP-treated mice.  
The values represent the means ± S.E.M. ***P < 0.001 compared with the control 
group. #P < 0.05, and ##P < 0.01 compared with the MPTP group. n=4 per group. 
 
Fig. 3A: D-Ala2-GIP-GLU-PAL reduced the astrocyte activation in the substantia nigra of 
mice induced by MPTP. (A – D) – GFAP positive cell numbers were increased following 
treatment with MPTP, and reduced by D-Ala2-GIP-GLU-PAL. A: Saline; B 
–D-Ala2-GIP-GLU-PAL; C – MPTP; D – MPTP + D-Ala2-GIP-GLU-PAL. Scale bar in image C: 
50μm. Graph: Quantification of area of GFAP positive cell in the substantia nigra 
demonstrates that saline-treated and D-Ala2-GIP-GLU-PAL-treated mouse groups had 
significantly lower expression of GFAP than the MPTP-treated mouse group.   
Fig. 3B: D-Ala2-GIP-GLU-PAL reduced the microglia activation in the substantia nigra of 
mice induced by MPTP. (A – D) – IBA1 expression was increased following treatment 
with MPTP, and reduced by D-Ala2-GIP-GLU-PAL. A: Saline; B: D-Ala2-GIP-GLU-PAL; C: 
MPTP; D: MPTP + D-Ala2-GIP-GLU-PAL. Scale bar in image C: 50μm. Graph: 
Quantification of area of IBA1 positive cell in the substantia nigra demonstrates that 
saline-treated and D-Ala2-GIP-GLU-PAL-treated mouse groups had significantly lower 
expression of IBA1 than the MPTP-treated mouse group. The values represent the 
means ± S.E.M. ***P < 0.001 compared with the control group. ###P < 0.001 compared 
with the MPTP group. n=4 per group. 
 
Fig. 4: D-Ala2-GIP-GLU-PAL reversed the reduction of synaptophysin in the substantia 
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nigra of mice induced by MPTP. The values represents the means ± S.E.M. ***P < 0.001 
compared with the control group. ##P < 0.01 compared with the MPTP group. n=4 per 
group. 
 
Fig. 5: D-Ala2-GIP-GLU-PAL reversed the increase of ratio of Bax/Bcl-2 in the substantia 
nigra of mice induced by MPTP. The values represents the means ± S.E.M. ***P < 0.001 
compared with the control group. ##P < 0.01 compared with the MPTP group. n=4 per 
group. 
 
Fig. 6: D-Ala2-GIP-GLU-PAL moderate reversed the decrease of p-CREBS133 in the 
substantia nigra of mice induced by MPTP. The values represents the means ± S.E.M. 
***P < 0.001 compared with the control group, #P < 0.05 compared with the MPTP 
group. n=4 per group. 
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